Buda P - Search Results

1

The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events.

Krus U, King BC, Nagaraj V, Gandasi NR, Sjölander J, Buda P, Garcia-Vaz E, Gomez MF, Ottosson-Laakso E, Storm P, Fex M, Vikman P, Zhang E, Barg S, Blom AM, Renström E. Krus U, et al. Among authors: buda p. Cell Metab. 2014 May 6;19(5):883-90. doi: 10.1016/j.cmet.2014.03.001. Epub 2014 Apr 10. Cell Metab. 2014. PMID: 24726385 Free article.

2

Eukaryotic translation initiation factor 3 subunit e controls intracellular calcium homeostasis by regulation of cav1.2 surface expression.

Buda P, Reinbothe T, Nagaraj V, Mahdi T, Luan C, Tang Y, Axelsson AS, Li D, Rosengren AH, Renström E, Zhang E. Buda P, et al. PLoS One. 2013 May 30;8(5):e64462. doi: 10.1371/journal.pone.0064462. Print 2013. PLoS One. 2013. PMID: 23737983 Free PMC article.

3

Elevated Basal Insulin Secretion in Type 2 Diabetes Caused by Reduced Plasma Membrane Cholesterol.

Nagaraj V, Kazim AS, Helgeson J, Lewold C, Barik S, Buda P, Reinbothe TM, Wennmalm S, Zhang E, Renström E. Nagaraj V, et al. Among authors: buda p. Mol Endocrinol. 2016 Oct;30(10):1059-1069. doi: 10.1210/me.2016-1023. Epub 2016 Aug 17. Mol Endocrinol. 2016. PMID: 27533789 Free PMC article.

4

CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.

Bazydlo-Guzenda K, Buda P, Matloka M, Mach M, Stelmach F, Dzida R, Smuga D, Hucz-Kalitowska J, Teska-Kaminska M, Vialichka V, Dubiel K, Kaminska B, Wieczorek M, Pieczykolan J. Bazydlo-Guzenda K, et al. Among authors: buda p. Mol Pharmacol. 2021 Oct;100(4):335-347. doi: 10.1124/molpharm.121.000260. Epub 2021 Aug 4. Mol Pharmacol. 2021. PMID: 34349026

5

Discovery and development of CPL207280 as new GPR40/FFA1 agonist.

Mach M, Bazydło-Guzenda K, Buda P, Matłoka M, Dzida R, Stelmach F, Gałązka K, Wąsińska-Kałwa M, Smuga D, Hołowińska D, Dawid U, Gurba-Bryśkiewicz L, Wiśniewski K, Dubiel K, Pieczykolan J, Wieczorek M. Mach M, et al. Among authors: buda p. Eur J Med Chem. 2021 Dec 15;226:113810. doi: 10.1016/j.ejmech.2021.113810. Epub 2021 Sep 1. Eur J Med Chem. 2021. PMID: 34537444

6

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.

Bazydlo-Guzenda K, Buda P, Mach M, Pieczykolan J, Kozlowska I, Janiszewski M, Drzazga E, Dominowski J, Ziolkowski H, Wieczorek M, Gad SC. Bazydlo-Guzenda K, et al. Among authors: buda p. PLoS One. 2021 Sep 23;16(9):e0257477. doi: 10.1371/journal.pone.0257477. eCollection 2021. PLoS One. 2021. PMID: 34555055 Free PMC article.

7

First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.

Bazydło-Guzenda K, Jarus-Dziedzic K, Gierczak-Pachulska A, Buda P, Rudzki PJ, Buś-Kwaśnik K, Juszczyk E, Tratkiewicz E, Rabczenko D, Segiet-Święcicka A, Wieczorek M. Bazydło-Guzenda K, et al. Among authors: buda p. Diabetes Obes Metab. 2024 Apr;26(4):1376-1385. doi: 10.1111/dom.15439. Epub 2024 Jan 11. Diabetes Obes Metab. 2024. PMID: 38204407

8

Influence of adalimumab on interleukin 12/23 signalling pathways in human keratinocytes treated with lipopolysaccharide A.

Buda P, Michalski P, Warmusz O, Michalska-Bańkowska A, Sirek T, Ossowski P, Bogdał P, Strojny D, Pisany-Syska A, Grabarek BO. Buda P, et al. Postepy Dermatol Alergol. 2023 Oct;40(5):647-654. doi: 10.5114/ada.2023.129272. Epub 2023 Jul 5. Postepy Dermatol Alergol. 2023. PMID: 38028419 Free PMC article.

9

A crossroads between dietary habits, alcohol consumption, and smoking in the clinical course of psoriasis: a narrative review.

Michalski P, Palazzo-Michalska V, Buda P, Michalska-Bańkowska A, Bańkowski M, Strojny D, Grabarek BO. Michalski P, et al. Among authors: buda p. Postepy Dermatol Alergol. 2023 Oct;40(5):599-605. doi: 10.5114/ada.2023.129308. Epub 2023 Jul 5. Postepy Dermatol Alergol. 2023. PMID: 38028418 Free PMC article. Review.

10

Evaluation of the safety profile and therapeutic efficacy of remdesivir in children with SARS-CoV-2 infection - a single-center, retrospective, cohort study.

Kautsch K, Wiśniowska J, Friedman-Gruszczyńska J, Buda P. Kautsch K, et al. Among authors: buda p. Eur J Pediatr. 2024 Feb;183(2):591-598. doi: 10.1007/s00431-023-05287-4. Epub 2023 Oct 21. Eur J Pediatr. 2024. PMID: 37864601 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page